ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0708

Differences in Treating Knee Osteoarthritis by Clinician Specialty
Abstract Number: 1851

Different Disease Activity Trajectories in Early Axial Spondyloarthritis Lead to Significantly Different Long-term Outcomes : A Cluster-based Analysis of the DESIR Cohort
Abstract Number: 0417

Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes
Abstract Number: 0016

Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Abstract Number: 1403

Differential Effect of Abatacept vs TNF Blockers, on the Frequency of Circulating Follicular Helper (Tfh) and Periperal Helper (Tph) T Cells in Rheumatoid Arthritis
Abstract Number: 1399

Differential Impacts of TNFa Inhibitors on the Expression of Th Cytokines
Abstract Number: 0482

Differential Influence of CDAI Components Based on Disease State in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Abstract Number: 0998

Differential Roles of TNFRI and TNFRII in the Morphology of Secondary Lymphoid Organs
Abstract Number: 1529

Differentially Expressed Chemokines and Cytokines in Peripheral Blood Mononuclear Cells (PBMCs) of Rheumatoid Arthritis (RA) Patients
Abstract Number: 0082

Diffuse Sclerosing Osteomyelitis of the Jaw: An Underdiagnosed Disease in Maxillofacial Surgery Department
Abstract Number: 1396

Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis
Abstract Number: 1380

Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Increases the Risk of Digital Ischemic Complications in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Abstract Number: 0830

Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Abstract Number: 1129

Discordance in Patient and Physician Assessment of Disease Activity in Relapsing Polychondritis
Abstract Number: 1213

Discrepancy Between the Multi-biomarker Disease Activity Score and Clinical Disease Activity Scores in a 2‑Part, Multicenter Study of Repository Corticotropin Injection (Acthar® Gel) for Patients with Persistently Active Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].